116 related articles for article (PubMed ID: 28088627)
1. The telomere-binding protein TRF2 is required for metronomic therapeutic effects of gemcitabine and capecitabine.
Lee WP; Lan KH; Li CP; Chao Y; Hou MC; Lin HC; Lee SD
Biochim Biophys Acta Mol Basis Dis; 2017 Apr; 1863(4):917-928. PubMed ID: 28088627
[TBL] [Abstract][Full Text] [Related]
2. Gemcitabine causes telomere attrition by stabilizing TRF2.
Su CH; Chu WC; Lan KH; Li CP; Chao Y; Lin HC; Lee SD; Tsai YC; Lee WP
Eur J Cancer; 2012 Dec; 48(18):3465-74. PubMed ID: 22704123
[TBL] [Abstract][Full Text] [Related]
3. Metronomic chemotherapy with low-dose cyclophosphamide plus gemcitabine can induce anti-tumor T cell immunity in vivo.
Tongu M; Harashima N; Monma H; Inao T; Yamada T; Kawauchi H; Harada M
Cancer Immunol Immunother; 2013 Feb; 62(2):383-91. PubMed ID: 22926062
[TBL] [Abstract][Full Text] [Related]
4. XPF with mutations in its conserved nuclease domain is defective in DNA repair but functions in TRF2-mediated telomere shortening.
Wu Y; Zacal NJ; Rainbow AJ; Zhu XD
DNA Repair (Amst); 2007 Feb; 6(2):157-66. PubMed ID: 17055345
[TBL] [Abstract][Full Text] [Related]
5. Heregulin, a new regulator of telomere length in human cells.
Menendez JA; Rubio MA; Campisi J; Lupu R
Oncotarget; 2015 Nov; 6(37):39422-36. PubMed ID: 26318724
[TBL] [Abstract][Full Text] [Related]
6. Stem cell expansion during carcinogenesis in stem cell-depleted conditional telomeric repeat factor 2 null mutant mice.
Bojovic B; Ho HY; Wu J; Crowe DL
Oncogene; 2013 Oct; 32(43):5156-66. PubMed ID: 23178498
[TBL] [Abstract][Full Text] [Related]
7. Curcusone C induces telomeric DNA-damage response in cancer cells through inhibition of telomeric repeat factor 2.
Wang M; Cao J; Zhu JY; Qiu J; Zhang Y; Shu B; Ou TM; Tan JH; Gu LQ; Huang ZS; Yin S; Li D
Biochim Biophys Acta Proteins Proteom; 2017 Nov; 1865(11 Pt A):1372-1382. PubMed ID: 28870734
[TBL] [Abstract][Full Text] [Related]
8. Human XPF controls TRF2 and telomere length maintenance through distinctive mechanisms.
Wu Y; Mitchell TR; Zhu XD
Mech Ageing Dev; 2008 Oct; 129(10):602-10. PubMed ID: 18812185
[TBL] [Abstract][Full Text] [Related]
9. Capecitabine metronomic chemotherapy inhibits the proliferation of gastric cancer cells through anti-angiogenesis.
Yuan F; Shi H; Ji J; Cai Q; Chen X; Yu Y; Liu B; Zhu Z; Zhang J
Oncol Rep; 2015 Apr; 33(4):1753-62. PubMed ID: 25634241
[TBL] [Abstract][Full Text] [Related]
10. TRF2-tethered TIN2 can mediate telomere protection by TPP1/POT1.
Frescas D; de Lange T
Mol Cell Biol; 2014 Apr; 34(7):1349-62. PubMed ID: 24469404
[TBL] [Abstract][Full Text] [Related]
11. Abnormal function of telomere protein TRF2 induces cell mutation and the effects of environmental tumor‑promoting factors (Review).
Wang Z; Wu X
Oncol Rep; 2021 Aug; 46(2):. PubMed ID: 34278498
[TBL] [Abstract][Full Text] [Related]
12. Anti-angiogenesis participates in antitumor effects of metronomic capecitabine on colon cancer.
Shi H; Jiang J; Ji J; Shi M; Cai Q; Chen X; Yu Y; Liu B; Zhu Z; Zhang J
Cancer Lett; 2014 Jul; 349(2):128-35. PubMed ID: 24746899
[TBL] [Abstract][Full Text] [Related]
13. Elevated TRF2 in advanced breast cancers with short telomeres.
Diehl MC; Idowu MO; Kimmelshue KN; York TP; Jackson-Cook CK; Turner KC; Holt SE; Elmore LW
Breast Cancer Res Treat; 2011 Jun; 127(3):623-30. PubMed ID: 20625812
[TBL] [Abstract][Full Text] [Related]
14. Role of the TRF2 telomeric protein in cancer and ageing.
Muñoz P; Blanco R; Blasco MA
Cell Cycle; 2006 Apr; 5(7):718-21. PubMed ID: 16582635
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of low-dose oral metronomic dosing of the prodrug of gemcitabine, LY2334737, in human tumor xenografts.
Pratt SE; Durland-Busbice S; Shepard RL; Donoho GP; Starling JJ; Wickremsinhe ER; Perkins EJ; Dantzig AH
Mol Cancer Ther; 2013 Apr; 12(4):481-90. PubMed ID: 23371859
[TBL] [Abstract][Full Text] [Related]
16. Lack of TRF2 in ALT cells causes PML-dependent p53 activation and loss of telomeric DNA.
Stagno D'Alcontres M; Mendez-Bermudez A; Foxon JL; Royle NJ; Salomoni P
J Cell Biol; 2007 Dec; 179(5):855-67. PubMed ID: 18056407
[TBL] [Abstract][Full Text] [Related]
17. XPF nuclease-dependent telomere loss and increased DNA damage in mice overexpressing TRF2 result in premature aging and cancer.
Muñoz P; Blanco R; Flores JM; Blasco MA
Nat Genet; 2005 Oct; 37(10):1063-71. PubMed ID: 16142233
[TBL] [Abstract][Full Text] [Related]
18. Low-dose metronomic oral dosing of a prodrug of gemcitabine (LY2334737) causes antitumor effects in the absence of inhibition of systemic vasculogenesis.
Francia G; Shaked Y; Hashimoto K; Sun J; Yin M; Cesta C; Xu P; Man S; Hackl C; Stewart J; Uhlik M; Dantzig AH; Foster FS; Kerbel RS
Mol Cancer Ther; 2012 Mar; 11(3):680-9. PubMed ID: 22188817
[TBL] [Abstract][Full Text] [Related]
19. Elevated levels of TRF2 induce telomeric ultrafine anaphase bridges and rapid telomere deletions.
Nera B; Huang HS; Lai T; Xu L
Nat Commun; 2015 Dec; 6():10132. PubMed ID: 26640040
[TBL] [Abstract][Full Text] [Related]
20. TRF2 controls telomeric nucleosome organization in a cell cycle phase-dependent manner.
Galati A; Magdinier F; Colasanti V; Bauwens S; Pinte S; Ricordy R; Giraud-Panis MJ; Pusch MC; Savino M; Cacchione S; Gilson E
PLoS One; 2012; 7(4):e34386. PubMed ID: 22536324
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
